Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAs

Table 1 Clinical features of the HNSCC patients included in this study

Covariates	Type	Entire		Training		Validation		P value
Covariates	Type	Number	Percent	Number	Percent	Number	Percent	P value
Age
	≤ 60	246	49.10	116	46.40	130	51.79	0.2636
	> 60	255	50.90	134	53.60	121	48.21
Gender
	Female	133	26.55	70	28	63	25.10	0.5261
	Male	368	73.45	180	72	188	74.90
Smoking history
	No	113	22.55	58	23.20	55	21.91	0.9418
	Yes	378	75.45	187	74.80	191	76.10
	Unknown	10	2	5	2	5	1.99
Alcohol history
	No	158	31.54	82	32.80	76	30.28	0.285
	Yes	332	66.27	165	66	167	66.53
	Unknown	11	2.20	3	1.20	8	3.19
Histopathological grade
	G1	61	12.18	31	12.40	30	11.95	0.5758
	G2	299	59.68	150	60	149	59.36
	G3	119	23.75	61	24.40	58	23.11
	G4	2	0.40	–	–	2	0.80
	Unknown	20	3.99	8	3.20	12	4.78
T classification
	T1	33	6.59	16	6.40	17	6.77	0.0649
	T2	144	28.74	59	23.60	85	33.86
	T3	130	25.95	75	30	55	21.91
	T4	179	35.73	94	37.60	85	33.86
	Unknown	15	2.99	6	2.40	9	3.59
N classification
	N0	239	47.70	113	45.20	126	50.20	0.6737
	N1	80	15.97	45	18	35	13.94
	N2	153	30.54	78	31.20	75	29.88
	N3	7	1.40	4	1.60	3	1.20
	Unknown	22	4.39	10	4	12	4.78
Metastasis status
	M +	25	4.99	15	6	10	3.98	0.535
	M0	471	94.01	233	93.20	238	94.82
	Unknown	5	1	2	0.80	3	1.20
Stage
	Stage I	19	3.79	9	3.60	10	3.98	0.0938
	Stage II	95	18.96	36	14.40	59	23.51
	Stage III	102	20.36	57	22.80	45	17.93
	Stage IV	271	54.09	142	56.80	129	51.39
	Unknown	14	2.79	6	2.40	8	3.19

ISSN: 2047-783X